Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL-17231 in Advanced Solid Tumors with KRAS Mutation
NCT06078800Phase 1Recruiting
- Sponsor
- Yingli Pharma
- Start
- Sep 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YL17231 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), sponsored by Yingli Pharma. Primary endpoints: Dose Limiting Toxicities and Treatment Emergent Adverse Events. Started Sep 2023; status: recruiting.
02
Drugs
YL17231
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06078800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078800.